<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>几只生物科技和医疗保健股票在周五的盘后交易中显著上涨，受监管动态、融资更新和投资者情绪的推动。</p>
<p>Atossa Therapeutics, Inc. (ATOS) 上涨 12.98% 至 $0.69，涨幅 $0.080，因其宣布美国食品药品监督管理局孤儿药品发展办公室已授予 (Z)-endoxifen 用于杜氏肌营养不良症的孤儿药资格。这一资格标志着公司管线的一个重要里程碑。</p>
<p>ImmunityBio, Inc. (IBRX) 上涨 9.43% 至 $6.04，涨幅 $0.52。该公司报告称，其注册试验 QUILT-2.005 针对 BCG 初治非肌肉侵袭性膀胱癌的入组超出预期，超过 85% 的研究人群已入组。预计到 2026 年第二季度完成全部入组，并计划在 2026 年底向 FDA 提交生物制品许可申请。</p>
<p>Femasys Inc. (FEMY) 上涨 10.68% 至 $0.72，涨幅 $0.070。该公司在 1 月 14 日披露，纳斯达克批准其请求，给予额外 180 天的延长期限，以恢复符合最低$1.00 的出价要求。Femasys 现在有直到 2026 年 7 月 13 日的时间来满足上市标准。</p>
<p>Foghorn Therapeutics Inc. (FHTX) 上涨 4.02% 至 $6.26，涨幅 $0.24。该公司宣布以 30% 的溢价完成 5000 万美元的注册直接融资。此次发行包括普通股、预先融资的认股权证和按发行价格倍数定价的系列认股权证，毛收益总计约 5000 万美元。</p>
<p>Daré Bioscience, Inc. (DARE) 小幅上涨 1.04% 至 $1.95，涨幅 $0.020。该公司周五没有发布任何新闻，但股票仍在盘后交易中小幅上涨。</p>
<p>Theravance Biopharma, Inc. (TBPH) 上涨 5.00% 至 $21.01，涨幅 $1.00。与 Daré类似，该公司周五没有新闻，但股票在延长交易中上涨。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

标普生物技术 3 倍做空 - Direxion

FHTX

生物科技 ETF - VanEck Vectors

<p>几只生物科技和医疗股在周五的盘后交易中出现显著上涨，受到监管更新和投资者情绪的影响。Atossa Therapeutics (ATOS) 上涨 12.98%，至 0.69 美元，此前获得了 FDA 的孤儿药资格认证。ImmunityBio (IBRX) 上涨 9.43%，至 6.04 美元，因试验招募强劲。Femasys (FEMY) 上涨 10.68%，至 0.72 美元，因获得合规延期。Foghorn Therapeutics (FHTX) 在获得 5000 万美元融资后上涨 4.02%，至 6.26 美元。尽管没有新公告，Daré Bioscience (DARE) 和 Theravance Biopharma (TBPH) 也小幅上涨</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Several biotech and healthcare stocks posted notable gains in after-hours trading on Friday, driven by regulatory developments, financing updates, and investor sentiment.</p>
<div class="lb-trans"><p>几只生物科技和医疗保健股票在周五的盘后交易中显著上涨，受监管动态、融资更新和投资者情绪的推动。</p>
</div><p>Atossa Therapeutics, Inc. (ATOS) rose 12.98% to $0.69, up $0.080 after announcing that the U.S. Food and Drug Administration's Office of Orphan Products Development granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy. The designation marks a significant milestone for the company's pipeline.</p>
<div class="lb-trans"><p>Atossa Therapeutics, Inc. (ATOS) 上涨 12.98% 至 $0.69，涨幅 $0.080，因其宣布美国食品药品监督管理局孤儿药品发展办公室已授予 (Z)-endoxifen 用于杜氏肌营养不良症的孤儿药资格。这一资格标志着公司管线的一个重要里程碑。</p>
</div><p>ImmunityBio, Inc. (IBRX) advanced 9.43% to $6.04, gaining $0.52. The company reported that enrollment in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer has surpassed expectations, with more than 85% of the study population enrolled. Full enrollment is anticipated by the second quarter of 2026, with a biologics license application submission to the FDA targeted by year end 2026.</p>
<div class="lb-trans"><p>ImmunityBio, Inc. (IBRX) 上涨 9.43% 至 $6.04，涨幅 $0.52。该公司报告称，其注册试验 QUILT-2.005 针对 BCG 初治非肌肉侵袭性膀胱癌的入组超出预期，超过 85% 的研究人群已入组。预计到 2026 年第二季度完成全部入组，并计划在 2026 年底向 FDA 提交生物制品许可申请。</p>
</div><p>Femasys Inc. (FEMY) climbed 10.68% to $0.72, up $0.070. On January 14, the company disclosed that Nasdaq approved its request for an additional 180-day extension to regain compliance with the minimum $1.00 bid price requirement. Femasys now has until July 13, 2026 to meet the listing standard.</p>
<div class="lb-trans"><p>Femasys Inc. (FEMY) 上涨 10.68% 至 $0.72，涨幅 $0.070。该公司在 1 月 14 日披露，纳斯达克批准其请求，给予额外 180 天的延长期限，以恢复符合最低$1.00 的出价要求。Femasys 现在有直到 2026 年 7 月 13 日的时间来满足上市标准。</p>
</div><p>Foghorn Therapeutics Inc. (FHTX) gained 4.02% to $6.26, adding $0.24. The company announced the closing of a $50 million registered direct financing at a 30% premium. The offering included common stock, pre-funded warrants, and series warrants priced at multiples of the issue price, with gross proceeds totaling approximately $50 million.</p>
<div class="lb-trans"><p>Foghorn Therapeutics Inc. (FHTX) 上涨 4.02% 至 $6.26，涨幅 $0.24。该公司宣布以 30% 的溢价完成 5000 万美元的注册直接融资。此次发行包括普通股、预先融资的认股权证和按发行价格倍数定价的系列认股权证，毛收益总计约 5000 万美元。</p>
</div><p>Daré Bioscience, Inc. (DARE) edged higher by 1.04% to $1.95, up $0.020. The company did not release any news on Friday, but shares still managed modest after-hours gains.</p>
<div class="lb-trans"><p>Daré Bioscience, Inc. (DARE) 小幅上涨 1.04% 至 $1.95，涨幅 $0.020。该公司周五没有发布任何新闻，但股票仍在盘后交易中小幅上涨。</p>
</div><p>Theravance Biopharma, Inc. (TBPH) gained 5.00% to $21.01, adding $1.00. Similar to Daré, the company had no news on Friday, yet shares advanced in extended trading.</p>
<div class="lb-trans"><p>Theravance Biopharma, Inc. (TBPH) 上涨 5.00% 至 $21.01，涨幅 $1.00。与 Daré类似，该公司周五没有新闻，但股票在延长交易中上涨。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

After-Hours Gainers: ATOS, IBRX, FEMY, FHTX, DARE, TBPH

rttnews

Foghorn Therapeutics

美国制药 ETF - iShares

ImmunityBio

医疗业 ETF - SPDR

Theravance生物制药

动态生物技术与基因组 ETF - Invesco

美国医药设备 ETF - iShares

Femasys

医药突破 ETF - ALPS

基因改革 ETF - ARK

2 倍做多纳斯达克生物技术 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

标普生物技术 ETF - SPDR

Dare Bioscience

标普健康医疗设备 ETF - SPDR

医疗业 ETF - Vanguard

标普全球医疗股指数 ETF - iShares

Atossa Therapeutics

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

盘后上涨的股票包括：Atossa Therapeutics, ImmunityBio, Femasys, Foghorn Therapeutics, Dare Bioscience, Theravance BioPharma